Bank Of The West Trimmed By $612,000 Its American Tower New (AMT) Holding; Biospecifics Technologies Has 1.08 Sentiment

February 15, 2018 - By wolcottdaily

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $285.77 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 25 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Bank Of The West decreased American Tower Corp New (AMT) stake by 6.19% reported in 2017Q3 SEC filing. Bank Of The West sold 4,500 shares as American Tower Corp New (AMT)’s stock rose 18.69%. The Bank Of The West holds 68,234 shares with $9.33 million value, down from 72,734 last quarter. American Tower Corp New now has $58.10 billion valuation. The stock decreased 0.61% or $0.83 during the last trading session, reaching $135.48. About 4.83 million shares traded or 98.79% up from the average. American Tower Corporation (NYSE:AMT) has risen 23.66% since February 15, 2017 and is uptrending. It has outperformed by 6.96% the S&P500.

Bank Of The West increased Spdr Gold Trust (GLD) stake by 6,219 shares to 46,580 valued at $5.66M in 2017Q3. It also upped Broadcom Ltd stake by 5,621 shares and now owns 43,637 shares. Apple Inc (NASDAQ:AAPL) was raised too.

Since August 18, 2017, it had 0 insider buys, and 8 insider sales for $19.04 million activity. 5,000 shares valued at $717,450 were sold by REEVE PAMELA D A on Thursday, August 24. The insider TAICLET JAMES D JR sold $4.74M. DiSanto Edmund had sold 10,000 shares worth $1.38 million on Friday, September 22. Sharma Amit had sold 20,747 shares worth $2.90M on Friday, August 18. The insider THOMPSON SAMME L sold 5,000 shares worth $715,800. Another trade for 1,584 shares valued at $228,793 was sold by SHARBUTT DAVID E.

Investors sentiment increased to 1.2 in 2017 Q3. Its up 0.04, from 1.16 in 2017Q2. It increased, as 36 investors sold AMT shares while 287 reduced holdings. 102 funds opened positions while 287 raised stakes. 378.31 million shares or 1.55% less from 384.25 million shares in 2017Q2 were reported. Washington Trust reported 0.52% in American Tower Corporation (NYSE:REIT). State Board Of Administration Of Florida Retirement System owns 632,344 shares. Braun Stacey Assoc accumulated 78,253 shares. 3,348 are owned by Adirondack. Angelo Gordon LP owns 88,800 shares. Moore Mngmt Limited Partnership holds 350,000 shares. Silvercrest Asset Mngmt Limited Liability Co holds 0.02% in American Tower Corporation (NYSE:REIT) or 11,998 shares. Waverton Invest Management Ltd owns 49,124 shares. Assetmark Incorporated reported 0.02% stake. Mitsubishi Ufj & Banking Corporation reported 918,370 shares. Texas-based Cullen Frost Bankers has invested 0.36% in American Tower Corporation (NYSE:REIT). Amf Pensionsforsakring reported 617,669 shares stake. Horrell Inc accumulated 3,000 shares. Avalon Advsrs holds 0.42% or 95,658 shares in its portfolio. Sentry Invs has 0.3% invested in American Tower Corporation (NYSE:REIT).

Among 19 analysts covering American Tower Corporation (NYSE:AMT), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. American Tower Corporation had 68 analyst reports since August 6, 2015 according to SRatingsIntel. Morgan Stanley maintained the shares of AMT in report on Wednesday, December 13 with “Overweight” rating. The stock of American Tower Corporation (NYSE:REIT) has “Buy” rating given on Monday, August 28 by Citigroup. The stock of American Tower Corporation (NYSE:REIT) earned “Buy” rating by Oppenheimer on Thursday, July 27. The firm has “Buy” rating given on Wednesday, August 17 by Argus Research. The rating was initiated by Macquarie Research with “Outperform” on Tuesday, December 6. The rating was maintained by Oppenheimer on Tuesday, August 8 with “Buy”. The stock has “Buy” rating by Jefferies on Monday, August 7. As per Wednesday, November 1, the company rating was maintained by KeyBanc Capital Markets. The firm earned “Buy” rating on Monday, October 23 by Cowen & Co. Macquarie Research maintained the shares of AMT in report on Friday, July 28 with “Buy” rating.

Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on March, 21. They expect $0.39 earnings per share, down 2.50% or $0.01 from last year’s $0.4 per share. BSTC’s profit will be $2.80 million for 25.48 P/E if the $0.39 EPS becomes a reality. After $0.37 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts 5.41% EPS growth.

Jw Asset Management Llc holds 2.51% of its portfolio in BioSpecifics Technologies Corp. for 73,649 shares. Northpointe Capital Llc owns 135,657 shares or 0.67% of their US portfolio. Moreover, Elk Creek Partners Llc has 0.5% invested in the company for 170,102 shares. The California-based Rice Hall James & Associates Llc has invested 0.32% in the stock. Ativo Capital Management Llc, a Illinois-based fund reported 22,592 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: